Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

81 through 90 of 324

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : Rise in endometrial cancer affects Black women more than white women

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People concerned about their risk for endometrial cancer

The New York Times calls attention to the increase in a type of cancer of the uterus called endometrial cancer and how it disproportionately affects Black women. The article provides useful information about endometrial cancer while raising awareness of a significant and growing health disparity.  (Posted 8/16/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Physical activity may decrease fatigue associated with cancer treatment

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Cancer patients who are experiencing fatigue related to cancer or its treatment.

Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines.  (Posted 8/1/22). Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: Medium-High

Article : How your ovarian cancer diagnosis can help your relatives

Relevance: High

Quality of Writing: Medium-High

Most relevant for: People diagnosed with ovarian cancer

This media article provides tips from experts and the CDC for talking to family members after a diagnosis of ovarian cancer. It highlights which family members may be at risk of developing ovarian cancer or passing on genes that increase risk. The article provides links to resources, talking points, alternative methods of communication and potential reactions. (Posted 7/28/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Risk-reducing ovarian cancer surgery and quality of life

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with an inherited BRCA mutation

People with an inherited BRCA gene mutation are recommended to have surgery to remove their ovaries before the age of natural menopause to reduce their risk of ovarian cancer.  This surgery can cause short-term and long-term effects. This study assesses the quality of life among people who have their fallopian tubes surgically removed and later have their ovaries removed compared to people who have their ovaries and fallopian tubes removed at the same time.  (Posted 7/26/22). Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : A win for some patients with HER2-negative metastatic breast cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with HER2-low metastatic breast cancer

A drug used to treat HER2-positive breast cancer improved survival in people with metastatic breast cancers that were previously considered HER2-negative. These results change practice guidelines for metastatic breast cancer and reclassify HER2 tumor marker status as “HER2-low” to guide treatment. (Posted 7/18/22)

Update: On 08/05/2022 the FDA approved Enhertu to treat people with metastatic, HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or who developed disease recurrence during or within six months of completing chemotherapy. Enhertu is also approved for treatment of people with metastatic HER2-positive breast cancer who progressed after prior anti-HER2 treatment. Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : The hidden financial burden of treating cancer care symptoms

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who are experiencing side effects due to cancer treatment or cancer.

Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Do artificial sweeteners increase the risk of cancer?

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who consume artificial sweeteners

A large study of adults in France suggests that artificial sweeteners may increase the risk of certain cancers. (posted 6/21/2022). Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Metastatic prostate cancer cases increased as screening use declined

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who are concerned about their own or their loved one’s risk of prostate cancer

The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

View Related Clinical Trials

Article : Breast cancer risk for transgender men with inherited mutations

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: Transgender men with an inherited mutation

There is little information related to the risks and treatment options for transgender men and nonbinary people who are at high-risk for breast cancer due to an inherited BRCA1 or BRCA2 mutation. We review an expert viewpoint on the implications of a BRCA mutation for transgender men undergoing breast removal as part of their gender-affirming care plan. (posted 5/19/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : New drug approved for metastatic prostate cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who have been diagnosed with metastatic prostate cancer.

The FDA approved a new treatment for metastatic castration-resistant prostate cancer. They also approved a test that can be used to identify patients who would benefit from this new treatment.  (Posted 5/10/22)

Este artículo está disponible en español.

Read More